# Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

> **NCT03824964** · EARLY_PHASE1 · UNKNOWN · sponsor: **Allife Medical Science and Technology Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Refractory B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD19/CD22 CAR NK Cells

## Key facts

- **NCT ID:** NCT03824964
- **Lead sponsor:** Allife Medical Science and Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824964, "Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03824964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*